DOJ says Novo Nordisk’s claim that HHS's 340B contract pharmacy advisory opinion would make it break the law “is mere legerdemain.”

DOJ Cites 1996 HRSA Letter to PhRMA in Request to Dismiss Novo Nordisk’s 340B Contract Pharmacy Suit

Novo Nordisk’s claim that a federal legal advisory opinion on 340B contract pharmacy would make it unlawfully transfer its drugs to ineligible pharmacies and ineligible patients “is mere legerdemain” (slight of hand), government lawyers for U.S. Health and Human Services (HHS) Secretary Xavier Becerra told a federal district judge in Trenton, N.J., Tuesday.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report